sam:
Funds are shorting "biotech in general", not BTRN. No, I'm just indicating that, for some issues, the "liquidation in sympathy" is overwhelming.
No, the company has plenty of cash. Further, the Board is a solid "do business and try to find scientific excellence" bunch.
The releases issued in the past two days, to Joe Public who is sick of biotech, look like science fiction. They aren't. They are solid efforts to rewrite the science of transplantation.
But, that's not where we should be focused near-term. We should be watching MEDI's trials and that 10% or greater royalty. This is biotech's best bargain among many bargains.... the potential upside is MEGA, and it can come from one of several programs (leverage) or relatively near-term (MEDI trails).
Disclosure: it could also go down..... belongs in a basket that diversifies risk, or it doesn't belong in a portfolio at all. I own it and have a vested interest in its appreciation.
Rick |
